The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope.

Trial Profile

The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Quetiapine (Primary) ; Escitalopram; Fluoxetine; Paroxetine; Sertraline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 24 Jun 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top